250 related articles for article (PubMed ID: 16306272)
1. Glibenclamide-induced apoptosis is specifically enhanced by expression of the sulfonylurea receptor isoform SUR1 but not by expression of SUR2B or the mutant SUR1(M1289T).
Hambrock A; de Oliveira Franz CB; Hiller S; Osswald H
J Pharmacol Exp Ther; 2006 Mar; 316(3):1031-7. PubMed ID: 16306272
[TBL] [Abstract][Full Text] [Related]
2. Resveratrol binds to the sulfonylurea receptor (SUR) and induces apoptosis in a SUR subtype-specific manner.
Hambrock A; de Oliveira Franz CB; Hiller S; Grenz A; Ackermann S; Schulze DU; Drews G; Osswald H
J Biol Chem; 2007 Feb; 282(5):3347-56. PubMed ID: 17138562
[TBL] [Abstract][Full Text] [Related]
3. Effect of two amino acids in TM17 of Sulfonylurea receptor SUR1 on the binding of ATP-sensitive K+ channel modulators.
Hambrock A; Kayar T; Stumpp D; Osswald H
Diabetes; 2004 Dec; 53 Suppl 3():S128-34. PubMed ID: 15561900
[TBL] [Abstract][Full Text] [Related]
4. Stoichiometry of sulfonylurea-induced ATP-sensitive potassium channel closure.
Dörschner H; Brekardin E; Uhde I; Schwanstecher C; Schwanstecher M
Mol Pharmacol; 1999 Jun; 55(6):1060-6. PubMed ID: 10347249
[TBL] [Abstract][Full Text] [Related]
5. Tissue specificity of sulfonylureas: studies on cloned cardiac and beta-cell K(ATP) channels.
Gribble FM; Tucker SJ; Seino S; Ashcroft FM
Diabetes; 1998 Sep; 47(9):1412-8. PubMed ID: 9726229
[TBL] [Abstract][Full Text] [Related]
6. Rat homolog of sulfonylurea receptor 2B determines glibenclamide sensitivity of ROMK2 in Xenopus laevis oocyte.
Tanemoto M; Vanoye CG; Dong K; Welch R; Abe T; Hebert SC; Xu JZ
Am J Physiol Renal Physiol; 2000 Apr; 278(4):F659-66. PubMed ID: 10751228
[TBL] [Abstract][Full Text] [Related]
7. 17beta-Estradiol modulates apoptosis in pancreatic beta-cells by specific involvement of the sulfonylurea receptor (SUR) isoform SUR1.
Ackermann S; Hiller S; Osswald H; Lösle M; Grenz A; Hambrock A
J Biol Chem; 2009 Feb; 284(8):4905-13. PubMed ID: 19095654
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a mutant sulfonylurea receptor SUR2B with high affinity for sulfonylureas and openers: differences in the coupling to Kir6.x subtypes.
Hambrock A; Löffler-Walz C; Russ U; Lange U; Quast U
Mol Pharmacol; 2001 Jul; 60(1):190-9. PubMed ID: 11408614
[TBL] [Abstract][Full Text] [Related]
9. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide.
Sunaga Y; Gonoi T; Shibasaki T; Ichikawa K; Kusama H; Yano H; Seino S
Eur J Pharmacol; 2001 Nov; 431(1):119-25. PubMed ID: 11716850
[TBL] [Abstract][Full Text] [Related]
10. Different molecular sites of action for the KATP channel inhibitors, PNU-99963 and PNU-37883A.
Cui Y; Tinker A; Clapp LH
Br J Pharmacol; 2003 May; 139(1):122-8. PubMed ID: 12746230
[TBL] [Abstract][Full Text] [Related]
11. Potassium channel openers require ATP to bind to and act through sulfonylurea receptors.
Schwanstecher M; Sieverding C; Dörschner H; Gross I; Aguilar-Bryan L; Schwanstecher C; Bryan J
EMBO J; 1998 Oct; 17(19):5529-35. PubMed ID: 9755153
[TBL] [Abstract][Full Text] [Related]
12. Glibenclamide binding to sulphonylurea receptor subtypes: dependence on adenine nucleotides.
Hambrock A; Löffler-Walz C; Quast U
Br J Pharmacol; 2002 Aug; 136(7):995-1004. PubMed ID: 12145099
[TBL] [Abstract][Full Text] [Related]
13. Molecular basis and characteristics of KATP channel in human corporal smooth muscle cells.
Insuk SO; Chae MR; Choi JW; Yang DK; Sim JH; Lee SW
Int J Impot Res; 2003 Aug; 15(4):258-66. PubMed ID: 12934053
[TBL] [Abstract][Full Text] [Related]
14. Selectivity of repaglinide and glibenclamide for the pancreatic over the cardiovascular K(ATP) channels.
Stephan D; Winkler M; Kühner P; Russ U; Quast U
Diabetologia; 2006 Sep; 49(9):2039-48. PubMed ID: 16865362
[TBL] [Abstract][Full Text] [Related]
15. Interaction of the sulfonylthiourea HMR 1833 with sulfonylurea receptors and recombinant ATP-sensitive K(+) channels: comparison with glibenclamide.
Russ U; Lange U; Löffler-Walz C; Hambrock A; Quast U
J Pharmacol Exp Ther; 2001 Dec; 299(3):1049-55. PubMed ID: 11714894
[TBL] [Abstract][Full Text] [Related]
16. Identification of the high-affinity tolbutamide site on the SUR1 subunit of the K(ATP) channel.
Ashfield R; Gribble FM; Ashcroft SJ; Ashcroft FM
Diabetes; 1999 Jun; 48(6):1341-7. PubMed ID: 10342826
[TBL] [Abstract][Full Text] [Related]
17. Investigation of the molecular assembly of beta-cell K(ATP) channels.
Mikhailov MV; Mikhailova EA; Ashcroft SJ
FEBS Lett; 2000 Sep; 482(1-2):59-64. PubMed ID: 11018523
[TBL] [Abstract][Full Text] [Related]
18. Characterization of two novel forms of the rat sulphonylurea receptor SUR1A2 and SUR1BDelta31.
Gros L; Trapp S; Dabrowski M; Ashcroft FM; Bataille D; Blache P
Br J Pharmacol; 2002 Sep; 137(1):98-106. PubMed ID: 12183335
[TBL] [Abstract][Full Text] [Related]
19. Coexpression with the inward rectifier K(+) channel Kir6.1 increases the affinity of the vascular sulfonylurea receptor SUR2B for glibenclamide.
Russ U; Hambrock A; Artunc F; Löffler-Walz C; Horio Y; Kurachi Y; Quast U
Mol Pharmacol; 1999 Nov; 56(5):955-61. PubMed ID: 10531400
[TBL] [Abstract][Full Text] [Related]
20. Sensitivity of Kir6.2-SUR1 currents, in the absence and presence of sodium azide, to the K(ATP) channel inhibitors, ciclazindol and englitazone.
McKay NG; Kinsella JM; Campbell CM; Ashford ML
Br J Pharmacol; 2000 Jun; 130(4):857-66. PubMed ID: 10864893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
